Abbott's Humira Ad Makes Unsupported Claims: FDA

Law360, New York (December 29, 2008, 12:00 AM EST) -- The U.S. Food and Drug Administration has issued a warning to Abbott Laboratories, saying that an advertisement for the pharmaceutical company's arthritis and psoriasis treatment Humira is misleading and makes claims not supported by medical evidence.

In a letter dated Dec. 18 and posted on the FDA's Web site Wednesday, the agency told Abbott that an advertisement it placed is misleading because it “suggests that Humira is useful in a broader range of conditions or patients than has been demonstrated by substantial evidence or substantial clinical...
To view the full article, register now.